fashion -WSS

fashion

author：hotspot 2025-09-27 19:01:54 - browse：32149

A new lawsuit accuses the health insurer Cigna of denying claims in bulk. Julia Rendleman/Getty Images for Eventive Marketing

A new lawsuit accuses Cigna of using an algorithm to automatically deny claims in bulk instead of individually reviewing each case, putting patients on the hook for bills the health insurer otherwise would have paid.

The complaint filed Monday in the Eastern District of California says Cigna uses a system called PXDX to identify discrepancies between diagnoses and the tests and services it covers for those ailments. The company then allegedly denies claims in bulk without looking into each coverage request. California law requires insurers to give each claim a “thorough, fair, and objective investigation.”

Once the claims are denied, the company allegedly has its physician reviewers sign off on batches of denials without opening each patient’s files to conduct detailed reviews. The complaint cites a March ProPublica article, which found that over a period of two months in 2022, Cigna doctors denied over 300,000 requests for payment using PXDX, spending an average of 1.2 seconds “reviewing” each request. One doctor alone denied 121,000 claims in that time period, according to the article.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
Next article： Liver decline slowed by off

WSS

Beware the threat of staffing cuts at the CDC

Cancer drug shortages' outsize impact on ovarian cancer patients

The pain doctors face in trying to build their families

Eye stem cell transplant could help restore vision in injured people

The pain doctors face in trying to build their families

Study finds gene variants tied to breast cancer risk in Black women

focus

fashion

entertainment

BioMarin wins approval for gene therapy to treat hemophilia A

ProMED sees offers of support, but its future remains unclear

Anesthesiologist group: stop taking Ozempic before surgery

Cancer drug shortages' outsize impact on ovarian cancer patients

Medicare proposal to cover medical devices draws a mixed reaction

Making the case for fair compensation in clinical trials

Affirmative action in medical school literally saved lives

Lung cancer is America's deadliest cancer. Yet so few get screened

Drug repurposing or repositioning? The language matters

Beware the threat of staffing cuts at the CDC

focus

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

New definition of a human embryo proposed amid rapid advances

New definition of a human embryo proposed amid rapid advances

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

New definition of a human embryo proposed amid rapid advances

At flashy new research hub, AstraZeneca lays out ambitious growth goals

knowledge

leisure time

focus

explore